Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

44.27
-1.0000-2.21%
Pre-market: 45.000.7300+1.65%04:53 EDT
Volume:910.11K
Turnover:40.15M
Market Cap:2.74B
PE:51.33
High:45.23
Open:45.23
Low:43.27
Close:45.27
Loading ...

Protagonist Therapeutics Shares up 3.9% Premarket After Co Reports Higher Q4 Profit

THOMSON REUTERS
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M

MT Newswires Live
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98

MT Newswires Live
·
21 Feb

Protagonist Therapeutics Inc: Qtrly License and Collaboration Revenue $ 170.6 Mln

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Basic EPS USD 2.11

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Net Income USD 131.674 Million VS. Ibes Estimate USD 22.5 Million

THOMSON REUTERS
·
21 Feb

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ACCESS Newswire
·
21 Feb

JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
19 Feb

Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals?

Simply Wall St.
·
14 Feb

Protagonist Therapeutics participates in a conference call with Truist

TIPRANKS
·
08 Feb

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

Protagonist Therapeutics (PTGX) Receives a Buy from Truist Financial

TIPRANKS
·
07 Feb

Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating

TIPRANKS
·
07 Feb

Promising Potential of Rusfertide in Treating Polycythemia Vera Drives Buy Rating for Protagonist Therapeutics

TIPRANKS
·
07 Feb

Positive Outlook on Protagonist Therapeutics: Potential of Rusfertide in Addressing Polycythemia Vera Needs

TIPRANKS
·
07 Feb

JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
07 Feb

Protagonist Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
04 Feb

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

ACCESS Newswire
·
30 Jan

Protagonist Therapeutics Reports Granting of Inducement Awards

ACCESSWIRE
·
07 Jan

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

ACCESSWIRE
·
20 Dec 2024